JPRN-jRCT2031230210
Recruiting
Phase 2
A clinical trial of steroid therapy for patients with FCMD caused by a homozygous 3kb insertion in FKTN gene.
Ishigaki Keiko0 sites15 target enrollmentJuly 8, 2023
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Fukuyama-type congenital muscular dystrophy
- Sponsor
- Ishigaki Keiko
- Enrollment
- 15
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Patients with homozygous 3kb insertion in the fukutin gene and a definitive diagnosis of FCMD
- •2\) Patients aged 5 to 13 at the time of consent
- •3\) Patients whose legal guardian capable of providing informed consent has provided written informed consent upon thorough understanding of the study procedure. Efforts should be made so that the subjects themselves give voluntary assent after having been provided with an explanation according to their ability to understand.
- •4\) Patients who are expected to survive over one year
- •5\) Patients whose motor function has clearly deteriorated by confirming upper extremity function, shuffling distance, or sitting time at 2 points in the pre\-observation period and at least 3 months before
Exclusion Criteria
- •1\) History of hypersensitivity to the Prednisolone
- •2\) Patients with infections or systemic mycoses for which there are no effective antibacterial agents
- •3\) Patients with peptic ulcer
- •4\) Patients with tuberculous infections
- •5\) Patients with electrolyte abnormality
- •6\) Patients with thrombosis
- •7\) Patients with a history of acute myocardial infarction
- •8\) Patients with insomnia and panic reaction
- •9\) Patients who received other investigational drugs , study drugs or aspirin within 3 months before the start of administration of the Prednisolone
- •10\) Previous exposure to Prednisolone (Short\-term history of steroid treatment as acute treatment for bronchial asthma and short\-term history of topical drug treatment not intended for FCMD treatment are excluded.)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
A clinical trial of steroid therapy for patients with FCMD caused by a homozygous(hetrozygous) 3kb insertion in FKTN gene.Fukuyama-type congenital muscular dystrophyJPRN-jRCT2031230211Ishigaki Keiko20
Completed
Not Applicable
The efficacy of steroid therapy in the patient with Fukuyama congenital muscular dystrophyFukuyama congenital muscular dystrophyJPRN-UMIN000020715The department of Pediatrics, Tokyo Women's Medical University10
Completed
Phase 2
Phase IIb clinical trial of steroid therapy in patients with HAMJPRN-UMIN000023798St. Marianna University School of Medicine Hospital8
Completed
Not Applicable
Phase IIb clinical trial of steroid therapy in patients with HAM(Non progressor)HTLV-1-Associated-Myelopathy Tropical Spastic Paraparesis (HAM/TSP)JPRN-UMIN000024086St. Marianna University School of Medicine Hospital5
Completed
Phase 2
Phase IIb clinical trial of steroid therapy in patients with HAM(Slow progressor)HTLV-1-Associated-Myelopathy Tropical Spastic Paraparesis (HAM/TSP)JPRN-UMIN000024085St. Marianna University School of Medicine Hospital40